NCT04917809 2026-04-22
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT04754425 2026-02-06
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT03238196 2024-11-14
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT06328491 2024-03-25
Erdafitinib in Metastatic Steroid-cell Ovarian Cancer
University Health Network, Toronto
Phase NA Completed
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT06204614 2024-01-12
Drug Screening Using IMD in Bladder Cancer
Brigham and Women's Hospital
Phase EARLY_PHASE1 Unknown
NCT03999515 2023-09-28
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
University of Washington
Phase 2 Terminated
NCT03827850 2023-06-09
FIND
Lung Cancer Group Cologne
Phase 2 Terminated
NCT02952573 2020-09-17
Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement
University Health Network, Toronto
Phase 2 Terminated